Pharma Tech

Roche’s Tecentriq snags FDA label expansion in type of colon cancer

Oct 9, 2026, 10:37 AM

Read Full Article → Roche’s Tecentriq snags FDA label expansion in type of colon cancer

Translate article text

Choose a language and wait for the translated text.

Tecentriq is now the first immunotherapy indicated for dMMR colon cancer specifically, which is often linked to a higher risk of progression after surgery.